Anteris Technologies Global Corp. Files Registration Statement for Proposed US Initial Public Offering

Anteris Technologies Global Corp. (“ATGC”) today announced that it has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”), relating to the proposed initial public offering of its common stock (“Common Stock”) in the U.S. (the “Offering”). All Common Stock to be sold in the Offering will be offered by ATGC.

The amount of Common Stock to be offered and the price range for the proposed Offering have not yet been determined. The Offering is subject to market conditions and there can be no assurances as to whether or when the Offering may be completed, or as to the actual size, price or other terms of the Offering.

ATGC intends to list its Common Stock on the Nasdaq Global Select Market under the symbol “AVR.”

Following the Offering, ATGC intends to list its CHESS Depositary Interests (“CDIs”) (representing underlying shares of Common Stock on a 1 CDI-for-1 share of Common Stock basis) on the Australian Securities Exchange under the symbol “AVR.”

TD Cowen, Barclays and Cantor are acting as joint book-running managers for the proposed Offering, with Lake Street Capital Markets acting as lead manager.

The proposed Offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus relating to the proposed Offering may be obtained from: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by e-mail at TD.ECM_Prospectus@tdsecurities.com; Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue Edgewood, NY 11717, by telephone at (888) 603-5847 or by e-mail at Barclaysprospectus@broadridge.com; or Cantor, 110 East 59th Street, 6th Floor, New York, NY 10022, by telephone at (212) 915-1800 or by e-mail at prospectus@cantor.com.

A registration statement relating to the Common Stock has been filed with the SEC but has not yet become effective. The Common Stock may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

This announcement is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy the Common Stock, and shall not constitute an offer, solicitation or sale of the Common Stock in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About ATGC

ATGC was incorporated on January 29, 2024 for the purpose of reorganizing the operations of Anteris Technologies Ltd (“Anteris”), an Australian public company originally registered in Western Australia, Australia and listed on the Australian Securities Exchange (“ASX”), into a structure whereby the ultimate parent company will be a Delaware corporation.

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering potentially transformative solutions to structural heart disease patients.

Anteris’ lead product, DurAVR^®, is a transcatheter heart valve (THV) for treating aortic stenosis. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR^® THV is made using ADAPT^® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT^® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASUR^® Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR^® THV with balloon-expandable delivery, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241124424451/en/